AstraZeneca plc (AZN) on Thursday said an interim analysis of the Phase III VOLGA trial showed that perioperative treatment with Imfinzi combined with neoadjuvant enfortumab vedotin (EV) significantly improved event-free survival and overall survival in patients with muscle-invasive bladder cancer compared with standard of care.
The trial included patients who were ineligible for or declined cisplatin-based chemotherapy.
A combination of Imfinzi, Imjudo and EV also improved event-free survival, but overall survival results were not statistically significant at the interim analysis. The company said no new safety signals were identified.
Imfinzi is approved in more than 40 countries for patients with cisplatin-eligible muscle-invasive bladder cancer. Imfinzi combined with Bacillus Calmette-Guérin therapy for high-risk non-muscle-invasive bladder cancer is under regulatory review in the U.S., European Union, Japan and other countries. The drug is also being studied in locally advanced or metastatic disease in the Phase III NILE trial.
For comments and feedback contact: editorial@rttnews.com
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.